Found: 14
Select item for more details and to access through your institution.
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3297
- By:
- Publication type:
- Article
Prescription patterns of venetoclax in acute myeloid leukemia.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3298
- By:
- Publication type:
- Article
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3296
- By:
- Publication type:
- Article
TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3295
- By:
- Publication type:
- Article
Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3294
- By:
- Publication type:
- Article
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3293
- By:
- Publication type:
- Article
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3292
- By:
- Publication type:
- Article
Correction to Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience.
- Published in:
- 2024
- Publication type:
- Correction Notice
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3290
- By:
- Publication type:
- Article
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3289
- By:
- Publication type:
- Article
Clonal dynamics of Richter transformation in chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3282
- By:
- Publication type:
- Article
Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3279
- By:
- Publication type:
- Article
Correction to Staging FDG‐avidity in extranodal marginal zone lymphoma (EMZL) by disease location.
- Published in:
- 2024
- Publication type:
- Correction Notice
Issue Information.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3180
- Publication type:
- Article